+76.4%
VXUS vs GSK
+62.2%
+14.1%
-13.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | -1.9% | +2.4% | +0.8% |
| 7D | +1.0% | -1.8% | +2.8% | +1.3% |
| 30D | +2.2% | -2.2% | +4.4% | +2.5% |
| 3M | +3.0% | -1.8% | +4.8% | +3.1% |
| 6M | +10.7% | -10.6% | +21.3% | +12.6% |
| YTD | +17.8% | +4.4% | +13.4% | +16.6% |
| 1Y | +27.6% | +30.4% | -2.8% | +20.9% |
| All | +76.4% | +62.2% | +14.1% | +58.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling